Study Finds Neural Fingerprint in Five Psychedelics
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- The study combined 11 brain‑imaging datasets from five countries, analyzing more than 500 scans of 267 participants to map psychedelic effects.
- The five drugs—LSD, psilocybin, DMT, mescaline, and ayahuasca—produced a common ‘neural fingerprint’ indicating a shared impact on brain behavior.
- The drugs flattened the usual hierarchy of brain systems, leading to excessive cross‑talk between higher‑order thinking networks and primitive visual‑sensory networks.
- Higher‑order networks showed stronger communication with vision and sensation regions, while deeper changes appeared in habit‑learning and movement areas.
- The study found little reliable evidence that individual brain networks disintegrate under psychedelics, contrary to some earlier claims.
- Dr Danilo Bzdok said the work provides a solid foundation for psychedelic research, helping move the field from shaky ground toward reliable therapeutic evidence.
Why it matters: Clinicians and researchers gain a robust, large‑scale evidence base for psychedelic therapies, supporting their potential use in treating depression, schizophrenia, and PTSD, while the field moves beyond fragmented, small‑sample studies that have left it on uncertain footing and improve patient outcomes.
